Clobetasol Propionate in the Treatment of Plaque Psoriasis

  • Beatriz Feliz
    Universidad de Salamanca
  • Felice Musicco
    Instituto Fisioterapéutico Hospitalario de Roma
  • Raquel Alvarez
    Universidad de Salamanca raquelalvarez[at]usal.es

Abstract

Psoriasis is a common chronic disease with significant impairment in quality of life. As there is no cure, it often requires lifelong disease control to minimize the development of skin lesions and to relieve symptoms.

Psoriasis vulgaris, also called mild / moderate, is a type of psoriasis characterized by manifest localized involvement of a skin surface <10%. For this type of psoriasis, clinical studies have shown increased efficiency based on a combination treatment of topical corticosteroids class I (betamethasone dipropionate) 0.05% with salicylic acid 2-3%, unique in the market.

The aim of this study was the preparation of a master formula that combines clobetasol 0.015% incorporated into salicylic vaseline 6% (for non-hirsute area) and sweet al.mond oil with salicylic acid 6% (for the hirsute area) due to the absence of a preparation to ensure the prescribed concentrations and test the effectiveness of this preparation in a sample of patients with mild / moderate psoriasis who come to the hospital through PASI and IGA indexes.

  • Referencias
  • Cómo citar
  • Del mismo autor
  • Métricas

Clobetasol Propionate in the Treatment of Plaque Psoriasis. (2017). FarmaJournal, 2(1), 111-120. https://revistas.usal.es/cinco/index.php/2445-1355/article/view/15247

Similar Articles

1-10 of 14

You may also start an advanced similarity search for this article.

Author Biographies

Felice Musicco

Instituto Fisioterapéutico Hospitalario de Roma

Dirigente Farmacéutico - Instituto Fisioterapéutico hospitalario  IFO, Roma.  Tel +39 06 5266.2989-2047. Correo electrónico: 

Raquel Alvarez

Universidad de Salamanca

Profesora Contratada Doctor

Departamento de Ciencias Farmacéuticas

Campus Miguel Unamuno s/n

Facultad de Farmacia

37008 Salamanca

+ −